Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.50 |
| ▸ | MDM4 | O15151 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.44 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229718 | 0.89 | MDM4 (0.51) | CASP3MDM4TP53MDM2SLC17A5 | |
| SCHEMBL27749256 | 0.89 | MDM4 (0.51) | CASP3MDM4TP53MDM2SLC17A5 | |
| SCHEMBL30229529 | 0.89 | MDM4 (0.51) | CASP3MDM4TP53MDM2SLC17A5 | |
| SCHEMBL850332 | 0.89 | MDM4 (0.51) | CASP3MDM4TP53MDM2SLC17A5 | |
| SCHEMBL18795729 | 0.89 | MDM4 (0.51) | CASP3MDM4TP53MDM2SLC17A5 | |
| SCHEMBL16100914 | 0.86 | MDM4 (0.54) | CASP3MDM4TP53MDM2SLC17A5 | |
| SCHEMBL16100911 | 0.86 | MDM4 (0.54) | CASP3MDM4TP53MDM2SLC17A5 | |
| SCHEMBL850327 | 0.84 | MDM4 (0.42) | CASP3MDM4TP53MDM2SLC17A5 | |
| SCHEMBL377537 | 0.83 | MDM4 (0.49) | CASP3MDM4TP53MDM2SLC17A5 | |
| SCHEMBL24899350 | 0.83 | MDM2 (0.47) | CASP3MDM4TP53MDM2SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9109048-B2 | Inhibition of tumor growth | LYTIX BIOPHARMA AS (NO) | 2015-08-18 | — | — | US | disclosed |
| US-8283315-B2 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2012-10-09 | — | — | US | disclosed |
| US-8143211-B2 | Bioactive peptides | LYTIX BIOPHARMA AS (NO) | 2012-03-27 | — | — | US | disclosed |
| US-20080287346-A1 | Bioactive peptides | SVENDSEN JOHN SIGURD | 2008-11-20 | — | — | US | disclosed |
| US-20080019993-A1 | Inhibition of tumour growth | LYTIX BIOPHARMA AS (NO) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287346-A1 | Bioactive peptides | VIP, NGLY1, IAPP | CASP3 14/4885MDM4 425/4885TP53 42/4885 |
| US-20080019993-A1 | Inhibition of tumour growth | STING1, VIP, MIF | CASP3 147/4885MDM4 299/4885TP53 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.